<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<channel rdf:about="http://www.mdpi.com/rss/special_issue/hyphenated_chromatography">
		<title>Pharmaceutics: Applications of Hyphenated Chromatography Techniques in Pharmaceutics</title>
		<link>http://www.mdpi.com/journal/pharmaceutics/special_issues/hyphenated_chromatography/</link>
		<description>Dear Colleagues,
The special issue will cover recent applications of hyphenated chromatography techniques, e.g., LC-MS, LC/NMR, in formulation evaluation, stability testing, impurity characterization, ADME, and PK/PD studies for drug discovery and development.
Raymond N. Xu,  Ph. D.
Guest Editor

Submission
All manuscripts should be submitted to pharmaceutics@mdpi.com with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
 
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions   for Authors page. Pharmaceutics  is an international peer-reviewed Open Access quarterly journal  published by MDPI.
 
Please visit the Instructions     for  Authors page before submitting a  manuscript. For the first   couple  of issues, to be published in 2010, the Article Processing Charges (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
 </description>
								<items>
			<rdf:Seq>
							<rdf:li rdf:resource="http://www.mdpi.com/1999-4923/2/2/171/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1999-4923/2/2/105/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1999-4923/2/1/18/" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
	</channel>
	<item rdf:about="http://www.mdpi.com/1999-4923/2/2/171/">
	<title>Pharmaceutics, Vol. 2, Pages 171-181: Quantitative Determination of ABT-925 in Human Plasma by On-Line SPE and LC-MS/MS: Validation and Sample Analysis in Phase II Studies</title>
	<link>http://www.mdpi.com/1999-4923/2/2/171/</link>
	<description>A fully automated 96-well On-Line Solid Phase Extraction (SPE) followed by High Performance Liquid Chromatography (HPLC)-Tandem Mass Spectrometric (MS/MS) method for the determination of ABT-925 (2-{3-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-yl)-propyl-sulfanyl}-3H-pyrimidin-4-one fumarate) in human plasma was developed, validated and utilized in Phase II clinical studies. 50 µL of plasma sample was fortified with internal standard (IS, d8-ABT-925) and extracted on-line with Cohesive Turbo Flow Cyclone P HTLC column. The chromatographic separation was performed on Aquasil C18 (3 μm 50 × 3 mm) HPLC column with a mobile phase consisting of 50/50/0.1 (v/v/v) ACN/H2O/formic acid. The mass spectrometric measurement was conducted under positive ion mode using multiple reaction monitoring (MRM) of m/z 457.4 → 329.4 for analyte and m/z 465.5 → 337.5 for IS.The peak area ratio (analyte/IS) was used to quantitate ABT-925. A dynamic range of 0.0102 μg/mL to 5.24 μg/mL was established after the validation. The validated method was then used for two Phase II studies. To demonstrate the method reproducibility, approximately 10% of the incurred samples from one study were repeated in singlet. The repeated values were compared to the initial values. All repeated values agreed within ±15% of the mean values. </description>
	
	<guid>http://www.mdpi.com/1999-4923/2/2/171/</guid>
	<pubDate>Tue, 04 May 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>Pharmaceutics</prism:publicationName>
	<prism:publicationDate>2010-05-04</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>171</prism:startingPage>
		<prism:endingPage>181</prism:endingPage>
		<prism:issn>1999-4923</prism:issn>
	
	<dc:title>Quantitative Determination of ABT-925 in Human Plasma by On-Line SPE and LC-MS/MS: Validation and Sample Analysis in Phase II Studies</dc:title>
	<dc:date>2010-05-04</dc:date>
	<dc:identifier>doi: 10.3390/pharmaceutics2020171</dc:identifier>
		<dc:creator> Wan</dc:creator>
		<dc:creator> Rieser</dc:creator>
		<dc:creator> El-Shourbagy</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1999-4923/2/2/105/">
	<title>Pharmaceutics, Vol. 2, Pages 105-118: Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma</title>
	<link>http://www.mdpi.com/1999-4923/2/2/105/</link>
	<description>A novel bioanalytical method was developed and validated for the quantitative determination of erlotinib in human plasma by using the supported liquid extraction (SLE) sample cleanup coupled with hydrophilic interaction liquid chromatography and tandem mass spectrometric detection (HILIC-MS/MS). The SLE extract could be directly injected into the HILIC-MS/MS system for analysis without the solvent evaporation and reconstitution steps. Therefore, the method is simple and rapid. In the present method, erlotinib-d6 was used as the internal standard. The SLE extraction recovery was 101.3%. The validated linear curve range was 2 to 2,000 ng/mL based on a sample volume of 0.100-mL, with a linear correlation coefficient of &gt; 0.999. The validation results demonstrated that the present method gave a satisfactory precision and accuracy: intra-day CV &lt; 5.9% (</description>
	
	<guid>http://www.mdpi.com/1999-4923/2/2/105/</guid>
	<pubDate>Thu, 01 Apr 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>Pharmaceutics</prism:publicationName>
	<prism:publicationDate>2010-04-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>105</prism:startingPage>
		<prism:endingPage>118</prism:endingPage>
		<prism:issn>1999-4923</prism:issn>
	
	<dc:title>Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma</dc:title>
	<dc:date>2010-04-01</dc:date>
	<dc:identifier>doi: 10.3390/pharmaceutics2020105</dc:identifier>
		<dc:creator> Pan</dc:creator>
		<dc:creator> Jiang</dc:creator>
		<dc:creator> Chen</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1999-4923/2/1/18/">
	<title>Pharmaceutics, Vol. 2, Pages 18-29: Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent γ-Ketoaldehyde Scavenger, by LC/MS/MS</title>
	<link>http://www.mdpi.com/1999-4923/2/1/18/</link>
	<description>Levels of reactive γ-ketoaldehydes derived from arachidonate increase in diseases associated with inflammation and oxidative injury. To assess the biological importance of these γ-ketoaldehydes, we previously identified salicylamine as an effective γ-ketoaldehyde scavenger in vitro and in cells. To determine if salicylamine could be administered in vivo, we developed an LC/MS/MS assay to measure salicylamine in plasma and tissues. In mice, half-life (t1/2) was 62 minutes. Drinking water supplementation (1-10 g/L) generated tissue concentrations (10-500 μM) within the range previously shown to inhibit γ-ketoaldehydes in cells. Therefore, oral administration of salicylamine can be used to assess the contribution of γ-ketoaldehydes in animal models of disease.</description>
	
	<guid>http://www.mdpi.com/1999-4923/2/1/18/</guid>
	<pubDate>Mon, 01 Feb 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>Pharmaceutics</prism:publicationName>
	<prism:publicationDate>2010-02-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:endingPage>29</prism:endingPage>
		<prism:issn>1999-4923</prism:issn>
	
	<dc:title>Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent γ-Ketoaldehyde Scavenger, by LC/MS/MS</dc:title>
	<dc:date>2010-02-01</dc:date>
	<dc:identifier>doi: 10.3390/pharmaceutics2010018</dc:identifier>
		<dc:creator>Irene Zagol-Ikapitte</dc:creator>
		<dc:creator>Elena Matafonova</dc:creator>
		<dc:creator>Venkataraman Amarnath</dc:creator>
		<dc:creator>Christopher L. Bodine</dc:creator>
		<dc:creator>Olivier Boutaud</dc:creator>
		<dc:creator>Rommel G. Tirona</dc:creator>
		<dc:creator>John A. Oates</dc:creator>
		<dc:creator>L. Jackson Roberts II</dc:creator>
		<dc:creator>Sean S. Davies</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>


<cc:License rdf:about="http://creativecommons.org/licenses/by/3.0/">
	<cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
